Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 4Glioblastoma 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × fotemustine × Clear all
NCT00560118 2025-02-14

MGFOT1

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Terminated
12 enrolled
Dermatologic

Melanoma

NCT01069627 2018-12-06

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Hoffmann-La Roche

Phase 2 Completed
20 enrolled 21 charts
Dermatologic

Melanoma

NCT01983124 2016-01-20

BeyPro1

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Phase 2 Completed
31 enrolled
Dermatologic

Melanoma

NCT01654692 2015-05-13

NIBIT-M1

Italian Network for Tumor Biotherapy

Phase 2 Completed
86 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡